BR112017008103A2 - composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. - Google Patents
composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.Info
- Publication number
- BR112017008103A2 BR112017008103A2 BR112017008103A BR112017008103A BR112017008103A2 BR 112017008103 A2 BR112017008103 A2 BR 112017008103A2 BR 112017008103 A BR112017008103 A BR 112017008103A BR 112017008103 A BR112017008103 A BR 112017008103A BR 112017008103 A2 BR112017008103 A2 BR 112017008103A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disease
- treating
- condition
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção proporciona compostos de fórmula (i) que são inibidores de jak, e como tal são úteis para o tratamento de doenças mediadas por jak tais como artrite reumatoide, asma, copd e câncer. a presente invenção proporciona novos compostos que são inibidores de jaks. a invenção também proporciona um método para o tratamento e a prevenção de doenças e distúrbios mediados por jak usando os novos compostos, bem como composições farmacêuticas contendo os compostos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/089139 WO2016061751A1 (en) | 2014-10-22 | 2014-10-22 | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
PCT/US2015/056541 WO2016064935A1 (en) | 2014-10-22 | 2015-10-21 | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017008103A2 true BR112017008103A2 (pt) | 2018-02-20 |
Family
ID=55760043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017008103A BR112017008103A2 (pt) | 2014-10-22 | 2015-10-21 | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10072025B2 (pt) |
EP (1) | EP3209296B1 (pt) |
JP (1) | JP2017531672A (pt) |
KR (1) | KR20170068585A (pt) |
CN (1) | CN107106547A (pt) |
AU (1) | AU2015336035A1 (pt) |
BR (1) | BR112017008103A2 (pt) |
CA (1) | CA2964375A1 (pt) |
MX (1) | MX2017005281A (pt) |
RU (1) | RU2017117248A (pt) |
WO (2) | WO2016061751A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017191098A1 (en) | 2016-05-05 | 2017-11-09 | F. Hoffmann-La Roche Ag | Pyrazole derivatives, compositions and therapeutic use thereof |
CN106749081B (zh) * | 2016-11-21 | 2019-06-25 | 浙江嘉圣生物医药有限公司 | 一种(s)-(4-溴-2-甲苯)(3-甲基吗啉)甲酮的制备方法 |
CA3043938A1 (en) | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
WO2018169777A1 (en) | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
PE20211237A1 (es) | 2017-12-22 | 2021-07-09 | Siegfried Ag | Preparacion de nicotina racemica mediante reaccion de etil nicotinato con n-vinilpirrolidona en presencia de una base de alcoholato y etapas de proceso posteriores |
CN111819181A (zh) * | 2018-05-10 | 2020-10-23 | 罗欣药业(上海)有限公司 | 苯并七元杂环类化合物、其制备方法、药物组合物及应用 |
WO2020064792A1 (en) * | 2018-09-27 | 2020-04-02 | F. Hoffmann-La Roche Ag | Heterocyclyl compounds for the treatment of autoimmune disease |
US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
CN114939349B (zh) * | 2022-05-03 | 2023-08-01 | 北京工业大学 | 一种用于气体分离的金属-有机空穴配合物混合基质膜的制备 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
CA2901766A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors |
US10059705B2 (en) * | 2013-03-19 | 2018-08-28 | Merck Sharp & Dohme Corp. | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors |
-
2014
- 2014-10-22 WO PCT/CN2014/089139 patent/WO2016061751A1/en active Application Filing
-
2015
- 2015-10-21 US US15/519,740 patent/US10072025B2/en active Active
- 2015-10-21 AU AU2015336035A patent/AU2015336035A1/en not_active Abandoned
- 2015-10-21 JP JP2017521567A patent/JP2017531672A/ja not_active Withdrawn
- 2015-10-21 MX MX2017005281A patent/MX2017005281A/es unknown
- 2015-10-21 CN CN201580070401.7A patent/CN107106547A/zh active Pending
- 2015-10-21 EP EP15853280.4A patent/EP3209296B1/en active Active
- 2015-10-21 KR KR1020177013258A patent/KR20170068585A/ko unknown
- 2015-10-21 BR BR112017008103A patent/BR112017008103A2/pt not_active Application Discontinuation
- 2015-10-21 WO PCT/US2015/056541 patent/WO2016064935A1/en active Application Filing
- 2015-10-21 RU RU2017117248A patent/RU2017117248A/ru not_active Application Discontinuation
- 2015-10-21 CA CA2964375A patent/CA2964375A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2017531672A (ja) | 2017-10-26 |
MX2017005281A (es) | 2017-08-15 |
EP3209296A4 (en) | 2018-04-11 |
WO2016061751A1 (en) | 2016-04-28 |
US20170240567A1 (en) | 2017-08-24 |
EP3209296A1 (en) | 2017-08-30 |
EP3209296B1 (en) | 2019-07-10 |
WO2016064935A1 (en) | 2016-04-28 |
KR20170068585A (ko) | 2017-06-19 |
CN107106547A (zh) | 2017-08-29 |
RU2017117248A (ru) | 2018-11-22 |
US10072025B2 (en) | 2018-09-11 |
CA2964375A1 (en) | 2016-04-28 |
AU2015336035A1 (en) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
EA201990221A1 (ru) | 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
EA201992128A1 (ru) | Конденсированные имидазопиперидиновые ингибиторы jak | |
BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
WO2013173441A3 (en) | Enhancer of zeste homolog 2 inhibitors | |
PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MX2019002438A (es) | Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus. | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
NZ702253A (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
EP4252856A3 (en) | Novel quinazolinones that inhibit the formation of tau oligomers and their method of use | |
MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
CL2017002229A1 (es) | Inhibidores de bace1. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |